Health Plan Best Practices - Implementing Retinal Disease Quality Improvement Initiatives with Payer/Provider Collaborations
Learn About:
Expert Faculty Presenters |
||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||
Target Audience
The primary target audience for this initiative includes medical directors, pharmacy directors, clinical pharmacists, specialty pharmacists, and quality directors, as well as network physicians affiliated with managed care organizations (MCOs), health systems, and other payer organizations. Other managed care professionals include nurses, case managers, policy administrators, utilization managers, C-suite executives, and IT professionals.
Statement of Need/Program Overview
This CE activity reviews the Retinal Disease Quality Improvement Roadmap, a practical framework developed through interviews with payer stakeholders and retinal specialists, followed by a multi-stakeholder best-practices workshop to identify opportunities for improving retinal disease screening, access, care coordination, and treatment continuity. The infographic highlights prioritized quality improvement strategies across short-, medium-, and long-term time horizons, with a focus on payer-provider collaboration to address operational barriers, streamline utilization management, expand early detection efforts, enhance data integration, and improve patient access to evidence-based retinal care. Managed care professionals will gain insights into actionable approaches for advancing administrative efficiency, care coordination, outcomes measurement, and value-based strategies that support timely treatment and vision preservation for individuals with retinal diseases, including diabetic retinopathy, diabetic macular edema, and age-related macular degeneration.
Educational Objectives
After completing this activity, participants should be able to demonstrate improved ability to:
Accreditation Information
 |
Joint Accreditation Statement |
Physician Continuing Medical Education
Medical Education Resources designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Pharmacy Education
Medical Education Resources designates this enduring material for 0.5 contact hour (0.05 CEUs) of the Accreditation Council for Pharmacy Education.
UAN: JA0003680-9999-26-291-H01-P
Activity Type: Knowledge-based
Please note: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.
Continuing Nursing Education
Medical Education Resources designates this enduring material for a maximum of 0.5 ANCC nursing contact hour. Nurses will be awarded contact hour upon successful completion of the activity.
Disclosure of Relevant Financial Relationships
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported relevant financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company. The authors reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:
| Name of Working Group Members/Planners | Reported Financial Relationship |
|---|---|
| Margaret Chang, MD | Grants/Research Support: Novartis, OcuTerra, Alexion, Outlook, Kodiak, 4DMT, Perceive, Kalaris, ONL, Character Biosciences Consulting Fees (eg. Ad boards): Genentech, AbbVie/RegenXBio, Astellas, Ocular Therapeutix, Oculis, Eyepoint, Boehringer, Ollin, Outlook, Adverum, Annexon, RetinAI, Eyebio/Merck Speakers’ Bureau: Genentech Stock Options: Ollin Bio |
| Darin Goldman, MD | Nothing to disclose. |
| Estay Greene, PharmD, MBA | Nothing to disclose. |
| Jonathan Jonisch, MD | Nothing to disclose. |
| Steve Kheloussi, PharmD, MBA, FAMCP | Nothing to disclose. |
| Michael Kobernick, MD, MS, MS-PopH, CPE | Nothing to disclose. |
| Michael Shannon, MD | Consulting Fees (ex. ad boards): Ventegra |
The content managers reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:
| Name of Content Managers | Reported Financial Relationship |
|---|---|
| Impact Education, LLC | No financial relationships to disclose |
| Planners at Medical Education Resources | No financial relationships to disclose |
DISCLAIMER
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Impact Education, LLC, and/or Regeneron Pharmaceuticals, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
FEE INFORMATION
There is no fee for this educational activity.
